<DOC>
	<DOC>NCT01315496</DOC>
	<brief_summary>This study is to determine whether the intravenous application of 'Ⅳ-Globulin S inj. (Human Immunoglobulin G)' can reduce mortality in patients with severe sepsis or septic shock.</brief_summary>
	<brief_title>GCIV as an Adjuvant Therapy for Community-Acquired Severe Sepsis or Septic Shock</brief_title>
	<detailed_description>A Placebo-controlled, Randomized, Double-blind, Multi-center, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous Administration of 'IV-Globulin S inj.(Human Immunoglobulin G)' as an Adjuvant Therapy in Adult Subjects with Community-Acquired Severe Sepsis or Septic Shock.</detailed_description>
	<mesh_term>Shock</mesh_term>
	<mesh_term>Sepsis</mesh_term>
	<mesh_term>Toxemia</mesh_term>
	<mesh_term>Shock, Septic</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulin G</mesh_term>
	<criteria>Patients with severe sepsis or septic shock, if all of the following criteria is satisfied. 1. Age ≥ 18 years 2. Proved or suspected infection in at least one site pneumonia urinary tract infection intraabdominal infection primary bloodstream infection skin and soft tissue infection 3. Three or more of the following a core temperature ≥ 38° C or ≤ 36° C a heart rate ≥ 90 beats/min a respiratory rate ≥ 20 breaths/min or PaCO2 ≤ 32 mmHg or use of mechanical ventilation for an acute process a white blood cell count ≥ 12000/mm3 or ≤ 4000/ mm3 or immature neutrophils &gt; 10% 4. Acute organ failure in one or more of the following kidney respiratory system blood system metabolic system circulatory system 5. APACHE score ≥ 20 and ≤ 29 6. Patient can treatment with GCIV in ICU within at least 48 hours 7. Informed consent 1. Pregnant or breastfeeding women 2. a weight &gt; 100kg 3. discharged from the hospital at least 14 days prior to new admission 4. Transferred from another hospital staying more than 48 hours 5. allergy or shock of IVIG 6. Treated with IVIG within the 12 weeks immediately preceding enrolment in this study 7. IgA deficiency 8. Hypernatremia or hyperhydration 9. Proved or suspected HIV or AIDS patients(CD4+ &lt;200mL) 10. Current participation in any study within the last 4 weeks 11. Do not resuscitate (DNR) status 12. Patient's death is considered imminent due to coexisting disease 13. physicians decision to exclude patients from this protocol 14. Immunocompromised patients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Human Immunoglobulin G</keyword>
	<keyword>Sepsis</keyword>
	<keyword>Septic shock</keyword>
</DOC>